Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Li-Fen Liu

Showing results (41-50 of 49) with videos related to

Pageof 5
Sort By:
You have reached the last page of results.This site can display upto 49 results.
Biochemical and Biophysical Research Communications|July 24, 2012
Hepatoma-derived growth factor stimulates podosome rosettes formation in NIH/3T3 cells through the activation of phosphatidylinositol 3-kinase/Akt pathwayMei-Lang Kung, Han-En Tsai, Tsung-Hui Hu, et al.
Oncotarget|April 12, 2014
Celecoxib suppresses hepatoma stemness and progression by up-regulating PTENTian-Huei Chu, Hoi-Hung Chan, Hsiao-Mei Kuo, et al.
Cancer Cell|November 6, 2020
Molecular Subsets in Renal Cancer Determine Outcome to Checkpoint and Angiogenesis BlockadeRobert J Motzer, Romain Banchereau, Habib Hamidi, et al.
Nature Communications|June 26, 2021
Molecular determinants of response to PD-L1 blockade across tumor typesRomain Banchereau, Ning Leng, Oliver Zill, et al.
Nature Medicine|May 15, 2020
High systemic and tumor-associated IL-8 correlates with reduced clinical benefit of PD-L1 blockadeKobe C Yuen, Li-Fen Liu, Vinita Gupta, et al.
Nature Medicine|February 6, 2021
Author Correction: High systemic and tumor-associated IL-8 correlates with reduced clinical benefit of PD-L1 blockadeKobe C Yuen, Li-Fen Liu, Vinita Gupta, et al.
Cell Reports. Medicine|January 4, 2023
CD8<sup>+</sup> T cell-intrinsic IL-6 signaling promotes resistance to anti-PD-L1 immunotherapyMahrukh A Huseni, Lifen Wang, Joanna E Klementowicz, et al.
Biorxiv : the Preprint Server for Biology|August 30, 2024
Cyclin A/B RxL Macrocyclic Inhibitors to Treat Cancers with High E2F ActivityShilpa Singh, Catherine E Gleason, Min Fang, et al.
Nature|August 20, 2025
Targeting G1-S-checkpoint-compromised cancers with cyclin A/B RxL inhibitorsShilpa Singh, Catherine E Gleason, Min Fang, et al.
Pageof 5

Showing results (41-50 of 49) with videos related to

Sort By:
Pageof 5
You have reached the last page of results.This site can display upto 49 results.
Biochemical and Biophysical Research Communications|July 24, 2012
Hepatoma-derived growth factor stimulates podosome rosettes formation in NIH/3T3 cells through the activation of phosphatidylinositol 3-kinase/Akt pathwayMei-Lang Kung, Han-En Tsai, Tsung-Hui Hu, et al.
Oncotarget|April 12, 2014
Celecoxib suppresses hepatoma stemness and progression by up-regulating PTENTian-Huei Chu, Hoi-Hung Chan, Hsiao-Mei Kuo, et al.
Cancer Cell|November 6, 2020
Molecular Subsets in Renal Cancer Determine Outcome to Checkpoint and Angiogenesis BlockadeRobert J Motzer, Romain Banchereau, Habib Hamidi, et al.
Nature Communications|June 26, 2021
Molecular determinants of response to PD-L1 blockade across tumor typesRomain Banchereau, Ning Leng, Oliver Zill, et al.
Nature Medicine|May 15, 2020
High systemic and tumor-associated IL-8 correlates with reduced clinical benefit of PD-L1 blockadeKobe C Yuen, Li-Fen Liu, Vinita Gupta, et al.
Nature Medicine|February 6, 2021
Author Correction: High systemic and tumor-associated IL-8 correlates with reduced clinical benefit of PD-L1 blockadeKobe C Yuen, Li-Fen Liu, Vinita Gupta, et al.
Cell Reports. Medicine|January 4, 2023
CD8<sup>+</sup> T cell-intrinsic IL-6 signaling promotes resistance to anti-PD-L1 immunotherapyMahrukh A Huseni, Lifen Wang, Joanna E Klementowicz, et al.
Biorxiv : the Preprint Server for Biology|August 30, 2024
Cyclin A/B RxL Macrocyclic Inhibitors to Treat Cancers with High E2F ActivityShilpa Singh, Catherine E Gleason, Min Fang, et al.
Nature|August 20, 2025
Targeting G1-S-checkpoint-compromised cancers with cyclin A/B RxL inhibitorsShilpa Singh, Catherine E Gleason, Min Fang, et al.
Pageof 5